Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?

Peter Vickerman, Natasha K. Martin, Anuradha Roy, Tara Beattie, Don Des Jarlais, Steffanie Strathdee, Lucas Wiessing, Matthew Hickman, Y. P. Bao, Waleska Caiaffa, Gonzalo Ralón, Diana Rossi, Laura Camoni, Barbara Suligoi, Nejc Bergant, Peer Brehm Christensen, Óscar Duarte, Sofia Santos, Carla Ribeiro, Ksenia EritsyanVeronika Odinokova, Konstantin Vyshinsky, Cinta Folch, Jordi Casabona, Anastasios Fotiou, Vivian Hope, Ilonka Horvath, Sharon Hutchinson, Violeta Bogdanova, Raina Ilieva, Jean Long, Catharina Matheï, Alexandr Muravsky, Leonie Prasad, Henrique Barros, Magdalena Rosinska, Marie Jauffret Roustide, Otilia Scutelniciuc, Fernando Vallejo, Uusküla Anneli, Bruno Guarita, Andre Noor, Luis de la Fuente, Marc Roelands, Michaël Hogge

Research output: Contribution to journalArticle

Abstract

Background: Amongst injecting drug users (IDUs), HIV is transmitted sexually and parenterally, but HCV is transmitted primarily parenterally. We assess and model the antibody prevalence of HCV amongst HIV-infected IDUs (denoted as HCV-HIV co-infection prevalence) and consider whether it proxies the degree of sexual HIV transmission amongst IDUs. Methods: HIV, HCV and HCV-HIV co-infection prevalence data amongst IDU was reviewed. An HIV/HCV transmission model was adapted. Multivariate model uncertainty analyses determined whether the model's ability to replicate observed data trends required the inclusion of sexual HIV transmission. The correlation between the model's HCV-HIV co-infection prevalence and estimated proportion of HIV infections due to injecting was evaluated. Results: The median HCV-HIV co-infection prevalence (prevalence of HCV amongst HIV-infected IDUs) was 90% across 195 estimates from 43 countries. High HCV-HIV co-infection prevalences (>80%) occur in most (75%) settings, but can be lower in settings with low HIV prevalence (<10%) or high HIV/HCV prevalence ratios (HIV prevalence divided by HCV prevalence > 0.75). The model without sexual HIV transmission reproduced some data trends but could not reproduce any epidemics with high HIV/HCV prevalence ratios (>0.85) or low HCV-HIV co-infection prevalence (<60%) when HIV prevalence > 10%. The model with sexual HIV transmission reproduced data trends more closely. The proportion of HIV infections due to injecting correlated with HCV-HIV co-infection prevalence; suggesting that up to 80/60/<20% of HIV infections could be sexually transmitted in settings with HCV-HIV co-infection prevalence between 50-60/70-80/>90%. Conclusion: Substantial sexual HIV transmission may occur in many IDU populations; HCV-HIV co-infection prevalence could signify its importance.

Original languageEnglish (US)
Pages (from-to)172-181
Number of pages10
JournalDrug and Alcohol Dependence
Volume132
Issue number1-2
DOIs
StatePublished - Sep 1 2013

Fingerprint

Drug Users
Coinfection
HIV Infections
HIV
Injections
Pharmaceutical Preparations
Hepatitis C Antibodies
Data communication systems
Proxy
Uncertainty

Keywords

  • Co-infection
  • Hepatitis C
  • HIV
  • Injecting drug use
  • Modelling

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? / Vickerman, Peter; Martin, Natasha K.; Roy, Anuradha; Beattie, Tara; Des Jarlais, Don; Strathdee, Steffanie; Wiessing, Lucas; Hickman, Matthew; Bao, Y. P.; Caiaffa, Waleska; Ralón, Gonzalo; Rossi, Diana; Camoni, Laura; Suligoi, Barbara; Bergant, Nejc; Christensen, Peer Brehm; Duarte, Óscar; Santos, Sofia; Ribeiro, Carla; Eritsyan, Ksenia; Odinokova, Veronika; Vyshinsky, Konstantin; Folch, Cinta; Casabona, Jordi; Fotiou, Anastasios; Hope, Vivian; Horvath, Ilonka; Hutchinson, Sharon; Bogdanova, Violeta; Ilieva, Raina; Long, Jean; Matheï, Catharina; Muravsky, Alexandr; Prasad, Leonie; Barros, Henrique; Rosinska, Magdalena; Roustide, Marie Jauffret; Scutelniciuc, Otilia; Vallejo, Fernando; Anneli, Uusküla; Guarita, Bruno; Noor, Andre; de la Fuente, Luis; Roelands, Marc; Hogge, Michaël.

In: Drug and Alcohol Dependence, Vol. 132, No. 1-2, 01.09.2013, p. 172-181.

Research output: Contribution to journalArticle

Vickerman, P, Martin, NK, Roy, A, Beattie, T, Des Jarlais, D, Strathdee, S, Wiessing, L, Hickman, M, Bao, YP, Caiaffa, W, Ralón, G, Rossi, D, Camoni, L, Suligoi, B, Bergant, N, Christensen, PB, Duarte, Ó, Santos, S, Ribeiro, C, Eritsyan, K, Odinokova, V, Vyshinsky, K, Folch, C, Casabona, J, Fotiou, A, Hope, V, Horvath, I, Hutchinson, S, Bogdanova, V, Ilieva, R, Long, J, Matheï, C, Muravsky, A, Prasad, L, Barros, H, Rosinska, M, Roustide, MJ, Scutelniciuc, O, Vallejo, F, Anneli, U, Guarita, B, Noor, A, de la Fuente, L, Roelands, M & Hogge, M 2013, 'Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?', Drug and Alcohol Dependence, vol. 132, no. 1-2, pp. 172-181. https://doi.org/10.1016/j.drugalcdep.2013.01.020
Vickerman, Peter ; Martin, Natasha K. ; Roy, Anuradha ; Beattie, Tara ; Des Jarlais, Don ; Strathdee, Steffanie ; Wiessing, Lucas ; Hickman, Matthew ; Bao, Y. P. ; Caiaffa, Waleska ; Ralón, Gonzalo ; Rossi, Diana ; Camoni, Laura ; Suligoi, Barbara ; Bergant, Nejc ; Christensen, Peer Brehm ; Duarte, Óscar ; Santos, Sofia ; Ribeiro, Carla ; Eritsyan, Ksenia ; Odinokova, Veronika ; Vyshinsky, Konstantin ; Folch, Cinta ; Casabona, Jordi ; Fotiou, Anastasios ; Hope, Vivian ; Horvath, Ilonka ; Hutchinson, Sharon ; Bogdanova, Violeta ; Ilieva, Raina ; Long, Jean ; Matheï, Catharina ; Muravsky, Alexandr ; Prasad, Leonie ; Barros, Henrique ; Rosinska, Magdalena ; Roustide, Marie Jauffret ; Scutelniciuc, Otilia ; Vallejo, Fernando ; Anneli, Uusküla ; Guarita, Bruno ; Noor, Andre ; de la Fuente, Luis ; Roelands, Marc ; Hogge, Michaël. / Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. In: Drug and Alcohol Dependence. 2013 ; Vol. 132, No. 1-2. pp. 172-181.
@article{a24709ae0b2f41aab8892ba5467f7563,
title = "Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?",
abstract = "Background: Amongst injecting drug users (IDUs), HIV is transmitted sexually and parenterally, but HCV is transmitted primarily parenterally. We assess and model the antibody prevalence of HCV amongst HIV-infected IDUs (denoted as HCV-HIV co-infection prevalence) and consider whether it proxies the degree of sexual HIV transmission amongst IDUs. Methods: HIV, HCV and HCV-HIV co-infection prevalence data amongst IDU was reviewed. An HIV/HCV transmission model was adapted. Multivariate model uncertainty analyses determined whether the model's ability to replicate observed data trends required the inclusion of sexual HIV transmission. The correlation between the model's HCV-HIV co-infection prevalence and estimated proportion of HIV infections due to injecting was evaluated. Results: The median HCV-HIV co-infection prevalence (prevalence of HCV amongst HIV-infected IDUs) was 90{\%} across 195 estimates from 43 countries. High HCV-HIV co-infection prevalences (>80{\%}) occur in most (75{\%}) settings, but can be lower in settings with low HIV prevalence (<10{\%}) or high HIV/HCV prevalence ratios (HIV prevalence divided by HCV prevalence > 0.75). The model without sexual HIV transmission reproduced some data trends but could not reproduce any epidemics with high HIV/HCV prevalence ratios (>0.85) or low HCV-HIV co-infection prevalence (<60{\%}) when HIV prevalence > 10{\%}. The model with sexual HIV transmission reproduced data trends more closely. The proportion of HIV infections due to injecting correlated with HCV-HIV co-infection prevalence; suggesting that up to 80/60/<20{\%} of HIV infections could be sexually transmitted in settings with HCV-HIV co-infection prevalence between 50-60/70-80/>90{\%}. Conclusion: Substantial sexual HIV transmission may occur in many IDU populations; HCV-HIV co-infection prevalence could signify its importance.",
keywords = "Co-infection, Hepatitis C, HIV, Injecting drug use, Modelling",
author = "Peter Vickerman and Martin, {Natasha K.} and Anuradha Roy and Tara Beattie and {Des Jarlais}, Don and Steffanie Strathdee and Lucas Wiessing and Matthew Hickman and Bao, {Y. P.} and Waleska Caiaffa and Gonzalo Ral{\'o}n and Diana Rossi and Laura Camoni and Barbara Suligoi and Nejc Bergant and Christensen, {Peer Brehm} and {\'O}scar Duarte and Sofia Santos and Carla Ribeiro and Ksenia Eritsyan and Veronika Odinokova and Konstantin Vyshinsky and Cinta Folch and Jordi Casabona and Anastasios Fotiou and Vivian Hope and Ilonka Horvath and Sharon Hutchinson and Violeta Bogdanova and Raina Ilieva and Jean Long and Catharina Mathe{\"i} and Alexandr Muravsky and Leonie Prasad and Henrique Barros and Magdalena Rosinska and Roustide, {Marie Jauffret} and Otilia Scutelniciuc and Fernando Vallejo and Uusk{\"u}la Anneli and Bruno Guarita and Andre Noor and {de la Fuente}, Luis and Marc Roelands and Micha{\"e}l Hogge",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.drugalcdep.2013.01.020",
language = "English (US)",
volume = "132",
pages = "172--181",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?

AU - Vickerman, Peter

AU - Martin, Natasha K.

AU - Roy, Anuradha

AU - Beattie, Tara

AU - Des Jarlais, Don

AU - Strathdee, Steffanie

AU - Wiessing, Lucas

AU - Hickman, Matthew

AU - Bao, Y. P.

AU - Caiaffa, Waleska

AU - Ralón, Gonzalo

AU - Rossi, Diana

AU - Camoni, Laura

AU - Suligoi, Barbara

AU - Bergant, Nejc

AU - Christensen, Peer Brehm

AU - Duarte, Óscar

AU - Santos, Sofia

AU - Ribeiro, Carla

AU - Eritsyan, Ksenia

AU - Odinokova, Veronika

AU - Vyshinsky, Konstantin

AU - Folch, Cinta

AU - Casabona, Jordi

AU - Fotiou, Anastasios

AU - Hope, Vivian

AU - Horvath, Ilonka

AU - Hutchinson, Sharon

AU - Bogdanova, Violeta

AU - Ilieva, Raina

AU - Long, Jean

AU - Matheï, Catharina

AU - Muravsky, Alexandr

AU - Prasad, Leonie

AU - Barros, Henrique

AU - Rosinska, Magdalena

AU - Roustide, Marie Jauffret

AU - Scutelniciuc, Otilia

AU - Vallejo, Fernando

AU - Anneli, Uusküla

AU - Guarita, Bruno

AU - Noor, Andre

AU - de la Fuente, Luis

AU - Roelands, Marc

AU - Hogge, Michaël

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background: Amongst injecting drug users (IDUs), HIV is transmitted sexually and parenterally, but HCV is transmitted primarily parenterally. We assess and model the antibody prevalence of HCV amongst HIV-infected IDUs (denoted as HCV-HIV co-infection prevalence) and consider whether it proxies the degree of sexual HIV transmission amongst IDUs. Methods: HIV, HCV and HCV-HIV co-infection prevalence data amongst IDU was reviewed. An HIV/HCV transmission model was adapted. Multivariate model uncertainty analyses determined whether the model's ability to replicate observed data trends required the inclusion of sexual HIV transmission. The correlation between the model's HCV-HIV co-infection prevalence and estimated proportion of HIV infections due to injecting was evaluated. Results: The median HCV-HIV co-infection prevalence (prevalence of HCV amongst HIV-infected IDUs) was 90% across 195 estimates from 43 countries. High HCV-HIV co-infection prevalences (>80%) occur in most (75%) settings, but can be lower in settings with low HIV prevalence (<10%) or high HIV/HCV prevalence ratios (HIV prevalence divided by HCV prevalence > 0.75). The model without sexual HIV transmission reproduced some data trends but could not reproduce any epidemics with high HIV/HCV prevalence ratios (>0.85) or low HCV-HIV co-infection prevalence (<60%) when HIV prevalence > 10%. The model with sexual HIV transmission reproduced data trends more closely. The proportion of HIV infections due to injecting correlated with HCV-HIV co-infection prevalence; suggesting that up to 80/60/<20% of HIV infections could be sexually transmitted in settings with HCV-HIV co-infection prevalence between 50-60/70-80/>90%. Conclusion: Substantial sexual HIV transmission may occur in many IDU populations; HCV-HIV co-infection prevalence could signify its importance.

AB - Background: Amongst injecting drug users (IDUs), HIV is transmitted sexually and parenterally, but HCV is transmitted primarily parenterally. We assess and model the antibody prevalence of HCV amongst HIV-infected IDUs (denoted as HCV-HIV co-infection prevalence) and consider whether it proxies the degree of sexual HIV transmission amongst IDUs. Methods: HIV, HCV and HCV-HIV co-infection prevalence data amongst IDU was reviewed. An HIV/HCV transmission model was adapted. Multivariate model uncertainty analyses determined whether the model's ability to replicate observed data trends required the inclusion of sexual HIV transmission. The correlation between the model's HCV-HIV co-infection prevalence and estimated proportion of HIV infections due to injecting was evaluated. Results: The median HCV-HIV co-infection prevalence (prevalence of HCV amongst HIV-infected IDUs) was 90% across 195 estimates from 43 countries. High HCV-HIV co-infection prevalences (>80%) occur in most (75%) settings, but can be lower in settings with low HIV prevalence (<10%) or high HIV/HCV prevalence ratios (HIV prevalence divided by HCV prevalence > 0.75). The model without sexual HIV transmission reproduced some data trends but could not reproduce any epidemics with high HIV/HCV prevalence ratios (>0.85) or low HCV-HIV co-infection prevalence (<60%) when HIV prevalence > 10%. The model with sexual HIV transmission reproduced data trends more closely. The proportion of HIV infections due to injecting correlated with HCV-HIV co-infection prevalence; suggesting that up to 80/60/<20% of HIV infections could be sexually transmitted in settings with HCV-HIV co-infection prevalence between 50-60/70-80/>90%. Conclusion: Substantial sexual HIV transmission may occur in many IDU populations; HCV-HIV co-infection prevalence could signify its importance.

KW - Co-infection

KW - Hepatitis C

KW - HIV

KW - Injecting drug use

KW - Modelling

UR - http://www.scopus.com/inward/record.url?scp=84881665312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881665312&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2013.01.020

DO - 10.1016/j.drugalcdep.2013.01.020

M3 - Article

C2 - 23453261

AN - SCOPUS:84881665312

VL - 132

SP - 172

EP - 181

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1-2

ER -